Health Technology Assessment Policy and Methods Review - Consultation 2
Results updated 10 Sep 2024
View all responses to Consultation 2 (A-Z)
The list below contains all submissions where consent has been provided for publication with attribution or anonymously. Each published submission comprises only questions answered by the respondent. Some submissions include supplementary documents.
Files:
- A. Menarini, 453.4 KB (PDF document)
- AbbVie, 527.9 KB (PDF document)
- AbbVie (Supplementary), 3.2 MB (PDF document)
- AccessCR, 428.4 KB (PDF document)
- Alexion, 455.2 KB (PDF document)
- Alexion (Supplementary), 351.3 KB (PDF document)
- Amgen, 449.8 KB (PDF document)
- Amgen (Supplementary), 2.4 MB (PDF document)
- Anita Lal, 3.4 MB (PDF document)
- Anita Lal & Jackie Roseleur, 242.9 KB (PDF document)
- Antegene, 461.1 KB (PDF document)
- Asthma Australia, 447.3 KB (PDF document)
- Asthma Australia (Supplementary), 392.2 KB (PDF document)
- AstraZeneca, 518.6 KB (PDF document)
- AstraZeneca (Supplementary), 1020.4 KB (PDF document)
- ausEE Inc., 447.0 KB (PDF document)
- Australasian Leukaemia & Lymphoma Group (ALLG) and Haematology Society of Australian & New Zealand (HSANZ), 463.8 KB (PDF document)
- Australian Antimicrobial Resistance Network (AAMRNet), 267.2 KB (PDF document)
- Australian Healthcare and Hospitals Association (AHHA), 507.2 KB (PDF document)
- Australian Patient Advocacy Alliance (APAA), 520.3 KB (PDF document)
- Australian Patient Advocacy Alliance (APAA) (Supplementary), 76.7 KB (PDF document)
- Australian Patients Association (APA), 117.2 KB (PDF document)
- Bayer, 461.6 KB (PDF document)
- Belinda Burns, 502.1 KB (PDF document)
- Biogen, 453.9 KB (PDF document)
- Biointelect, 172.7 KB (PDF document)
- BiomeBank, 437.3 KB (PDF document)
- Boehringer Ingelheim, 558.6 KB (PDF document)
- Brain Foundation, Migraine and Headache Australia, 283.2 KB (PDF document)
- Breast Cancer Network Australia (BCNA), 536.6 KB (PDF document)
- Breast Cancer Network Australia (BCNA) (Supplementary), 267.5 KB (PDF document)
- Brendan Shaw, 522.7 KB (PDF document)
- Bristol Myers Squibb Australia, 519.2 KB (PDF document)
- Bristol Myers Squibb Australia (Supplementary), 320.8 KB (PDF document)
- Cancer Organisations - Joint - Cancer Council, CNSA, COSA, PCPA, MOGA, 910.8 KB (PDF document)
- Cell & Gene Catalyst, 425.2 KB (PDF document)
- Cell & Gene Catalyst (Supplementary), 110.9 KB (PDF document)
- Centre for Sustainable Medicine, National University of Singapore, 426.1 KB (PDF document)
- Centre for Sustainable Medicine, National University of Singapore (Supplementary), 518.0 KB (PDF document)
- Childhood Dementia Initiative, 454.1 KB (PDF document)
- Christopher Steer, 457.2 KB (PDF document)
- Climate and Health Alliance, 443.0 KB (PDF document)
- Climate and Health Alliance (Supplementary), 260.5 KB (PDF document)
- Consumer Group Response - Joint response from 51 Organisations, 1.4 MB (PDF document)
- Consumers Health Forum (CHF), 459.7 KB (PDF document)
- Council of Australian Therapeutic Advisory Groups (CATAG), 184.5 KB (PDF document)
- Crohn's & Colitis Australia, 460.8 KB (PDF document)
- CSL, 515.0 KB (PDF document)
- CSL (Supplementary), 1.5 MB (PDF document)
- Dementia Australia, 210.0 KB (PDF document)
- Diabetes Alliance, 470.1 KB (PDF document)
- Diabetes Alliance (Supplementary), 856.5 KB (PDF document)
- Doctors for the Environment Australia - Kylie Astell, 422.1 KB (PDF document)
- Doctors for the Environment Australia - Ben Dunne, 419.4 KB (PDF document)
- Doctos for the Environment Australia (Supplementary), 86.9 KB (PDF document)
- Dominic Tilden, 457.6 KB (PDF document)
- Edward Giles, 445.1 KB (PDF document)
- Eli Lilly, 453.3 KB (PDF document)
- Eli Lilly (Supplementary), 200.6 KB (PDF document)
- Elif Ekinci, 433.7 KB (PDF document)
- Enhanced Consumer Engagement Process Co-Design Working Group, 225.6 KB (PDF document)
- Forbes McGain, 487.3 KB (PDF document)
- Genetic Support Network Victoria (GSNV), 474.9 KB (PDF document)
- Gilead, 485.6 KB (PDF document)
- Gilead (Supplementary), 176.9 KB (PDF document)
- GlaxoSmithKline (GSK), 453.6 KB (PDF document)
- GlaxoSmithKline (GSK) (Supplementary), 690.0 KB (PDF document)
- Haemophilia Foundation Australia (HFA), 547.0 KB (PDF document)
- Health Services Research Association of Australia and New Zealand (HSRAANZ), 443.3 KB (PDF document)
- Health Services Research Association of Australia and New Zealand (HSRAANZ) (Supplementary), 152.7 KB (PDF document)
- Healthy Environments and Lives (HEAL), 431.0 KB (PDF document)
- Healthy Environments and Lives (HEAL) (Supplementary), 336.1 KB (PDF document)
- Illumina, 527.8 KB (PDF document)
- Immunisation Coalition, 453.5 KB (PDF document)
- Ipsen, 425.7 KB (PDF document)
- Ipsen (Supplementary), 277.1 KB (PDF document)
- IQVIA, 519.2 KB (PDF document)
- Johnson & Johnson Innovative Medicines, 555.8 KB (PDF document)
- Johnson & Johnson Innovative Medicines (Supplementary), 1.0 MB (PDF document)
- Katy Bell (Response 1), 427.5 KB (PDF document)
- Katy Bell (Response 2), 425.4 KB (PDF document)
- Lai Heng Foong, 450.6 KB (PDF document)
- Leukaemia Foundation, 899.4 KB (PDF document)
- Life Saving Drugs Program (LSDP) Expert Panel, 166.4 KB (PDF document)
- Lung Foundation Australia, 528.3 KB (PDF document)
- Lynne Madden, 462.0 KB (PDF document)
- Martin Hensher, 452.5 KB (PDF document)
- Medical Technology Association of Australia (MTAA), 451.8 KB (PDF document)
- Medical Technology Association of Australia (MTAA) (Supplementary), 28.9 KB (PDF document)
- Medicines Australia, 2.1 MB (PDF document)
- Melanoma and Skin Cancer Advocacy Network (MSCAN), 454.8 KB (PDF document)
- Merck Sharp & Dohme (MSD), 529.0 KB (PDF document)
- Merck Sharp & Dohme (MSD) (Supplementary), 175.4 KB (PDF document)
- Metabolic Dietary Disorders Association (MDDA), 417.6 KB (PDF document)
- Mito Foundation, 516.7 KB (PDF document)
- Motor Neurone Disease (MND) Australia, 455.8 KB (PDF document)
- MTPConnect and AAMRNet, 427.7 KB (PDF document)
- Myeloma Australia & MSAG, 262.1 KB (PDF document)
- National Aboriginal Community Controlled Health Organisation (NACCHO), 544.7 KB (PDF document)
- National Blood Authority (NBA), 274.9 KB (PDF document)
- NeuroEndocrine Cancer Australia, 453.0 KB (PDF document)
- Neurological Alliance Australia, 509.9 KB (PDF document)
- Neurological Alliance Australia (Supplementary), 970.3 KB (PDF document)
- Novartis, 451.8 KB (PDF document)
- Novartis (Supplementary), 434.1 KB (PDF document)
- Omico, 468.3 KB (PDF document)
- Ovarian Cancer Australia (OCA), 440.8 KB (PDF document)
- Ovarian Cancer Australia (OCA) (Supplementary), 1005.6 KB (PDF document)
- Pain Australia, 536.6 KB (PDF document)
- Pain Australia (Supplementary), 255.9 KB (PDF document)
- Pathology Technology Australia (PTA), 454.9 KB (PDF document)
- Pathology Technology Australia (PTA) (Supplementary), 140.2 KB (PDF document)
- Paul Langley, 263.9 KB (PDF document)
- Penny Lello, 505.1 KB (PDF document)
- Pfizer, 456.8 KB (PDF document)
- Pfizer (Supplementary), 759.2 KB (PDF document)
- Pharmacy Guild of Australia, 252.8 KB (PDF document)
- Philip Clarke, 423.0 KB (PDF document)
- Philip Clarke (Supplementary), 223.0 KB (PDF document)
- PRIMCAT, 451.9 KB (PDF document)
- Public Health Association Australia (PHAA), 496.6 KB (PDF document)
- Public Health Association Australia (PHAA) (Supplementary), 498.8 KB (PDF document)
- Queensland Health, 1.7 MB (PDF document)
- Rare Voices Australia (RVA), 458.7 KB (PDF document)
- Rare Voices Australia (RVA) (Supplementary), 300.3 KB (PDF document)
- Roche, 534.1 KB (PDF document)
- Roche (Supplementary), 1.5 MB (PDF document)
- Royal Australasian College of Surgeons (RACS), 423.7 KB (PDF document)
- Royal Australasian College of Surgeons (RACS) (Supplementary), 262.4 KB (PDF document)
- Royal Australian and New Zealand College of Ophthalmologists (RANZCO), 437.4 KB (PDF document)
- Royal Australian College of General Practitioners (RACGP), 703.3 KB (PDF document)
- Royal College of Pathologists of Australasia (RCPA), 519.7 KB (PDF document)
- Rozalina Sarkezians, 515.2 KB (PDF document)
- Ruchi Kanojia, 458.2 KB (PDF document)
- Servier, 491.4 KB (PDF document)
- Shawview Consulting, 130.1 KB (PDF document)
- Society of Hospital Pharmacists Australia (SHPA), 463.3 KB (PDF document)
- Takeda, 417.4 KB (PDF document)
- Takeda (Supplementary), 312.0 KB (PDF document)
- Tracy Merlin, 570.6 KB (PDF document)
- UCB, 510.1 KB (PDF document)
- University of Melbourne 1, 150.3 KB (PDF document)
- University of Melbourne 2, 134.2 KB (PDF document)
- University of Sydney - NHMRC, 159.5 KB (PDF document)
- Wiser Healthcare, 430.3 KB (PDF document)
- Wiser Healthcare (Supplementary), 177.4 KB (PDF document)
- Anonymous Author 1, 1.5 MB (PDF document)
- Anonymous Author 2, 345.4 KB (PDF document)
- Anonymous Author 3, 61.2 KB (PDF document)
- Anonymous Author 4, 217.2 KB (PDF document)
- Anonymous Author 5, 908.3 KB (PDF document)
- Anonymous Author 6, 916.8 KB (PDF document)
- Anonymous Author 7, 928.5 KB (PDF document)
- Anonymous Author 8, 63.9 KB (PDF document)
- Anonymous Author 9, 498.3 KB (PDF document)
- Anonymous Author 10, 841.6 KB (PDF document)
- Anonymous Author 11, 2.2 MB (PDF document)
Overview
The Options Paper developed through the Health Technology Assessment Policy and Methods Review (HTA Review) has been published. You can access it through the 'Related' documents link, located at the end of this page.
This paper presents options for reform being considered by the Reference Committee to improve Australia’s HTA policies and methods and the funding and approval pathways.
The aim of this paper is to facilitate stakeholder feedback on the potential options for reform relating to:
- whether the proposed option/s will achieve the intended outcome
- what the potential impact on stakeholders may be, and
- any unintended outcomes or challenges stemming from the proposed options.
This Consultation phase will workshop the options for reform with stakeholders to understand potential implications and identify unintended outcomes.
Timeframe
The consultation commenced Thursday 25 January 2024. It will close at 23:59 AEDT on Friday 23 February 2024.
Health Technology Assessment Policy and Methods Review
The Health Technology Assessment (HTA) Policy and Methods Review (Review) is one of the key deliverables in the Strategic Agreement. The purpose of the HTA Review is to ensure Australia’s assessment processes keep pace with the rapid advances in health technology and minimise barriers to access.
Details about the HTA Review, its scope, initial consultations, and progress to date are available on the HTA Review webpage.
HTA Review Reference Committee
As outlined in the Strategic Agreement, the HTA Review is overseen by a Reference Committee. Appointments to the committee were announced by the Minister for Health on 27 October 2022.
Information on Reference Committee membership and functions are available on the HTA Review webpage.
Options for consultation
The Reference Committee has developed the options paper after thoroughly considering the evidence and input it has received to date.
The Reference Committee will consider the feedback received through this consultation, alongside other inputs, before deciding on final recommendations and delivering its final report.
Documents
To assist stakeholders the following documents are provided:
- Terms of reference (ToR)
- Consultation 2 plan
- Research and analysis papers
- Options Paper (see 'Related' documents at the end of this page)
How to take part
There will be opportunities to participate through: an online survey and attending an in-person or online workshops led by an independent facilitator.
Online survey:
- No question will be compulsory, you can choose to provide a response against as many or as few questions as you choose.
- Before the consultation closes, you have the option to leave an in-progress submission, and automatically be taken back to the last completed answer upon re-joining through the link below.
- The survey is hosted by an independent facilitator. You can access it at the bottom of the page.
Web and in-person workshops:
- You will be asked to detail any organisations you represent and topic area/s of your interest.
- Stakeholders can nominate a maximum of two representatives to attend the consultation workshop.
- Registrations will close on 14 February 2024.
- The online workshops will be held on 13th, 15th, 16th February 2024, from 10AM - 1PM AEDT.
- The in-person workshop will be held in Sydney on 19th February 2024, from 9:30AM - 3:30PM AEDT.
- Workshop summaries will be in the consultation report.
Consultation scope
In Scope: Comments and feedback on the Options Paper in relation to the proposed HTA review scope.
Out of scope: Feedback to include or remove topics outside of the terms of reference.
Accessibility arrangements
The HTA Review will seek to remedy any social, cultural, economic, and technical barriers for you to take part in the stakeholder engagement process. If you need alternative arrangements such as an interpreter, please email htareviewconsult@health.gov.au.
How will your submission and information be used
- Your submission and identifying information about you or your organisation will be made available in full to the HTA Review Reference Committee and may be summarised and analysed for review.
- Your submission and identifying information about you or your organisation may be made available to an entity engaged by the HTA Review to analyse submissions
- Unless requested otherwise, your submission and identifying information about you or your organisation will be published on the Department of Health and Aged Care Website and/or the Consultation Hub
- Your personal contact details will not be published.
Privacy notice
Your personal information is protected by law, including the Privacy Act 1988 (Privacy Act) and the Australian Privacy Principles (APPs), and is being collected by the Department, via Citizen Space, for the purposes of conducting a consultation process in relation to the HTA Review. Find out how we manage the personal information we collect about you through the Consultation for the HTA Review.
Audiences
- All
Interests
- All
- All
Share
Share on Twitter Share on Facebook